Rohto Pharmaceutical Co.,Ltd.
“Medium- to Long-Term Growth Strategy 2026” – Rolling Update of “Rohto Group Medium- to Long-Term Growth Strategy 2025–2035” and Notice Regarding the 2031 Financial Forecast
Rolling update of the Medium- to Long-Term Growth Strategy 2025–2035 and publication of the 2031 financial forecast. 2031 net sales 464 billion yen, operating income 59.8 billion yen, operating margin 12.9%, overseas sales ratio 56%, dividend payout ratio 40%, ROE targets, and adjustments from prior forecasts along with shareholder return policy.
Key Figures
- Net sales for FY2031: 4,640 hundred million yen
- Operating income for FY2031: 598 hundred million yen
- Overseas sales ratio: 56%
AI要約
Rolling Update of the Medium- to Long-Term Growth Strategy
This document reorganizes the financial forecast toward FY2031 through a rolling update of the "Rohto Group Medium- to Long-Term Growth Strategy 2025–2035." Segment-specific strategies are provided in related materials; the policy centers on expanding from self-care into professional care, deepening technological product capabilities, and building the foundation of the healthcare business.
FY2031 Financial Forecast and Shareholder Returns
For FY2031, net sales are projected at 464 billion yen, operating income at 59.8 billion yen, operating margin at 12.9%, and overseas ratio at 56%. The dividend payout ratio is set at 40% with a DOE target of 4.0%, pursuing a balance between a healthy financial position, growth investment, and shareholder returns. The company presents an upward revision from the prior FY2030 forecast and new standards after rolling.
Rohto Pharmaceutical Co.,Ltd.
Company overview · Stock price · Financial data · All IR
